Our findings are consistent with the previous study; therefore, we recommend the combined use of MR and clinical features with ML in future radiomics studies to verify their true diagnostic capabilities in predicting IDH mutation status in gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.